查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1608071

In Silico臨床試驗市場：按治療領域、階段、產業分類 - 2025-2030 年全球預測

In Silico Clinical Trials Market by Therapeutic Area (Infectious Diseases, Oncology), Phase (Phase I, Phase II, Phase III), Industry - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年In Silico臨床試驗市場規模為30.1億美元，預計2024年將達到31.9億美元，複合年成長率為7.01%，2030年將達到48.5億美元。

電腦In Silico臨床試驗被定義為用於預測新藥和設備的安全性和有效性的電腦模擬分析，是一個快速發展的領域，具有巨大的成長潛力。這些臨床試驗可以取代或補充體內和體外方法，大幅減少傳統臨床試驗固有的時間、成本和倫理問題。其應用範圍從藥物發現和開發到個人化醫療，並允許公司模擬無數在現實生活中不可能或不可能實現的場景。主要最終用戶包括製藥公司、醫療保健提供者、研究機構和監管機構，他們都受益於增強的預測能力和更快的監管審查。市場開拓將受到計算模型的進步、降低藥物開發成本的日益成長的需求以及對個人化醫療不斷成長的需求等因素的推動。人工智慧和機器學習等新技術存在潛在機會，可以進一步提高預測準確性和流程效率。然而，標準化不足、需要高品質資料以及監管障礙較高等限制因素給實施帶來了挑戰。相關人員必須關注這些問題，才能充分利用這一不斷成長的趨勢。需要創新的領域包括改進資料整合方法、開發強大的法規結構以及創建方便用戶使用的平台以促進更廣泛的採用。鑑於市場的動態性質，以技術快速進步和監管演變為特點，參與者應優先考慮策略夥伴關係和持續的研發投資，以保持競爭力。此外，隨著這些技術變得更加可信和獲得機構支持，它們具有改變現有藥物用途並確定新治療途徑的變革潛力，從而改善臨床研究格局，這將再形成行業並推動業務成長超越傳統界限。

主要市場統計
基準年[2023] 30.1億美元
預測年份 [2024] 31.9億美元
預測年份 [2030] 48.5億美元
複合年成長率（%） 7.01%

市場動態：揭示快速發展的In Silico臨床試驗市場的關鍵市場洞察

供需的動態交互作用正在改變In Silico臨床試驗市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 世界各地慢性病的流行以及對高效藥物日益成長的需求
    • 越來越需要更了解藥物和醫療設備的安全性和有效性
    • 藥物研發研發成本大幅增加
  • 市場限制因素
    • 新興經濟體對In Silico測驗的認知較低
  • 市場機會
    • In Silico臨床試驗的技術進步
    • 利用先進的計算建模和模擬工具
  • 市場挑戰
    • 蛋白質靈活性、分子構象和混雜性問題

波特的五力戰略工具駕馭In Silico臨床試驗市場

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解In Silico臨床試驗市場的外部影響

外部宏觀環境因素在塑造In Silico臨床試驗市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解In Silico臨床試驗市場的競爭狀況

In Silico臨床試驗市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

In Silico臨床試驗市場 FPNV 定位矩陣中供應商的績效評估

FPNV 定位矩陣是評估In Silico試驗市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了In Silico臨床試驗市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，In Silico臨床試驗市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地慢性病的盛行率不斷上升，增加了對有效藥物的需求。
      • 人們越來越需要更了解藥物和醫療設備。
      • 藥物研發研發成本大幅增加
    • 抑制因素
      • 新興經濟體對電腦測驗的認知較低
    • 機會
      • In Silico臨床試驗的技術進步
      • 利用先進的計算建模和模擬工具
    • 任務
      • 蛋白質靈活性、分子構象和混雜性問題
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第 6 章按治療領域In Silico臨床試驗市場

  • 感染疾病
  • 腫瘤學

第7章In Silico臨床試驗市場分階段

  • 第一階段
  • 第二階段
  • 第三階段

第 8 章In Silico臨床試驗市場：按行業

  • 醫療設備
  • 製藥

第9章北美和南美的In Silico臨床試驗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太電腦In Silico臨床試驗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的In Silico臨床試驗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Aganitha AI Inc.
  • GNS Healthcare
  • Insilico Medicine
  • InSilicoTrials Technologies
  • Instem Group of Companies
  • Labcorp Drug Development
  • Novadiscovery SAS
  • Thornton Tomasetti
  • ZMT Zurich MedTech AG
Product Code: MRR-742BD517F92A

The In Silico Clinical Trials Market was valued at USD 3.01 billion in 2023, expected to reach USD 3.19 billion in 2024, and is projected to grow at a CAGR of 7.01%, to USD 4.85 billion by 2030.

In silico clinical trials, defined as computer-simulated analyses used to predict the safety and efficacy of new drugs and devices, represent a burgeoning field poised for substantial growth. These trials provide a necessary alternative or complement to in vivo and in vitro methods, significantly reducing time, cost, and ethical concerns inherent in traditional clinical trials. Their application spans a wide array of uses, from drug discovery and development to personalized medicine, allowing companies to simulate myriad scenarios that might be impractical or impossible to conduct in real life. Key end-users include pharmaceutical companies, healthcare providers, research institutions, and regulatory agencies, all of which benefit from enhanced prediction capabilities and expedited regulatory reviews. Market growth is fueled by factors such as advances in computational modeling, the increasing necessity for cost reduction in drug development, and heightened demand for personalized medicine. Potential opportunities lie in emerging technologies like artificial intelligence and machine learning, which can further enhance predictive accuracy and process efficiency. However, adoption is challenged by limitations such as inadequate standardization, the necessity of high-quality data, and regulatory hurdles. It is crucial for stakeholders to focus on these issues to fully capitalize on the growing trend. Areas ripe for innovation include improving data integration methods, developing robust regulatory frameworks, and creating user-friendly platforms that facilitate broader adoption. Given the market's dynamic nature, characterized by rapid technological advancements and regulatory evolution, players should prioritize strategic partnerships and continuous R&D investment to stay competitive. Moreover, as these technologies become more trusted and institutionally supported, they hold the transformative potential to repurpose existing drugs and identify new therapeutic pathways, thereby reshaping the landscape of clinical research and facilitating business growth beyond conventional boundaries.

KEY MARKET STATISTICS
Base Year [2023] USD 3.01 billion
Estimated Year [2024] USD 3.19 billion
Forecast Year [2030] USD 4.85 billion
CAGR (%) 7.01%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving In Silico Clinical Trials Market

The In Silico Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases worldwide and need for efficient drugs
    • Growing need for better understanding of the safety and efficacy of a drug or a device
    • Significant rise in R&D expenditure for drug development
  • Market Restraints
    • Low awareness about in silico trials in the developing economies
  • Market Opportunities
    • Technological advancements in in silico clinical trials
    • Utilization of use advanced computational modeling and simulation tools
  • Market Challenges
    • Issues related to protein flexibility, molecule conformation, and promiscuity

Porter's Five Forces: A Strategic Tool for Navigating the In Silico Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the In Silico Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the In Silico Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the In Silico Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the In Silico Clinical Trials Market

A detailed market share analysis in the In Silico Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the In Silico Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the In Silico Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the In Silico Clinical Trials Market

A strategic analysis of the In Silico Clinical Trials Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the In Silico Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include Aganitha AI Inc., GNS Healthcare, Insilico Medicine, InSilicoTrials Technologies, Instem Group of Companies, Labcorp Drug Development, Novadiscovery SAS, Thornton Tomasetti, and ZMT Zurich MedTech AG.

Market Segmentation & Coverage

This research report categorizes the In Silico Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Area, market is studied across Infectious Diseases and Oncology.
  • Based on Phase, market is studied across Phase I, Phase II, and Phase III.
  • Based on Industry, market is studied across Medical Devices and Pharmaceutical.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases worldwide and need for efficient drugs
      • 5.1.1.2. Growing need for better understanding of the safety and efficacy of a drug or a device
      • 5.1.1.3. Significant rise in R&D expenditure for drug development
    • 5.1.2. Restraints
      • 5.1.2.1. Low awareness about in silico trials in the developing economies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in in silico clinical trials
      • 5.1.3.2. Utilization of use advanced computational modeling and simulation tools
    • 5.1.4. Challenges
      • 5.1.4.1. Issues related to protein flexibility, molecule conformation, and promiscuity
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. In Silico Clinical Trials Market, by Therapeutic Area

  • 6.1. Introduction
  • 6.2. Infectious Diseases
  • 6.3. Oncology

7. In Silico Clinical Trials Market, by Phase

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III

8. In Silico Clinical Trials Market, by Industry

  • 8.1. Introduction
  • 8.2. Medical Devices
  • 8.3. Pharmaceutical

9. Americas In Silico Clinical Trials Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific In Silico Clinical Trials Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa In Silico Clinical Trials Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aganitha AI Inc.
  • 2. GNS Healthcare
  • 3. Insilico Medicine
  • 4. InSilicoTrials Technologies
  • 5. Instem Group of Companies
  • 6. Labcorp Drug Development
  • 7. Novadiscovery SAS
  • 8. Thornton Tomasetti
  • 9. ZMT Zurich MedTech AG

LIST OF FIGURES

  • FIGURE 1. IN SILICO CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 2. IN SILICO CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. IN SILICO CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. IN SILICO CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IN SILICO CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IN SILICO CLINICAL TRIALS MARKET DYNAMICS
  • TABLE 7. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM IN SILICO CLINICAL TRIALS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 144. IN SILICO CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. IN SILICO CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023